| Zuo Yangsong,Shen Wenyi,Pu Juan,et al.Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with Ⅲa-pN2 non-small cell lung cancer：a randomized controlled trial[J].Chinese Journal of Radiological Medicine and Protection,2014,34(3):196-200 |
| Comparison of efficacy for postoperative chemotherapy and concurrent radiochemotherapy in patients with Ⅲa-pN2 non-small cell lung cancer：a randomized controlled trial |
| Received:July 15, 2013 |
| DOI：10.3760/cma.j.issn.0254-5098.2014.03.010 |
| KeyWords:Non-small cell lung cancer Surgery Ⅲa-pN2 Postoperative concurrent radiochemotherapy Survival |
| FundProject: |
| Author Name | Affiliation | E-mail | | Zuo Yangsong | Department of Radiation Oncology, People's Hospital of Lianshui County, Huai'an, Jiangsu 223400, China | | | Shen Wenyi | Department of Radiation Oncology, People's Hospital of Lianshui County, Huai'an, Jiangsu 223400, China | | | Pu Juan | Department of Radiation Oncology, People's Hospital of Lianshui County, Huai'an, Jiangsu 223400, China | | | Ji Jian | 南京医科大学附属淮安第一医院 | | | Tao Guangzhou | 南京医科大学附属淮安第一医院 | | | Yi Jianguo | 江苏省淮安市肿瘤医院 | | | Su Xilong | 江苏省淮安市第二人民医院 | | | Zhu Weiguo | 南京医科大学附属淮安第一医院 | | | Xu Dafu | 南京医科大学附属淮安第一医院 | jshaxdf@126.com |
|
| Hits: 4043 |
| Download times: 2435 |
| Abstract:: |
| Objective To compare the efficacy of postoperative concurrent radiochemotherapy (POCRT) and postoperative chemotherapy (POCT) alone on Ⅲa-pN2 non-small cell lung cancer (NSCLC).Methods A total of 140 postoperative patients with Ⅲa-pN2 NSCLC were randomly divided into 2 equal groups: POCRT and POCT groups. For chemotherapy paclitaxel at a dose of 175 mg/m2 and cisplatin a dose of 60 mg/m2 were injected intravenously at 1, 22, 43, and 64 d. Totally 4 cycles were adopted with an interval of 21 d. The patients in the POCRT group additionally received radiotherapy (50.4 Gy/28 times) at 1 d of treatment. Follow-up was conducted at least 5 years or until the death of the patients. Results The 5-year overall survival rate of the POCRT group was 37.9%, and the POCT group was 27.5%. The hazard ratio for death of the POCRT group was 0.69 (95% CI: 0.457-1.044, χ2=3.224,P>0.05). The 5-year relapse-free survival rate of the POCRT group was 30.3%, and the POCT group was 18.8%. The recurrence hazard ratio of the POCT group was 1.49 (95%CI: 1.008-2.204, χ2=4.193,P<0.05). Subgroup analysis revealed that POCRT significantly increased the overall survival rate of the patients with ≥2 pN2 lymph nodes (χ2=5.308,P<0.05). The POCRT group had a significantly lower relapse (χ2=5.308,P<0.05) and distant metastasis (χ2=3.840,P<0.05) rates as compared to that of the POCT group. One case died of pyemia and 9 cases who suffered from grades 3 or 4 radiation esophagitis. These 2 groups showed similar and tolerable hematologic toxicities. Conclusions Compared with POCT, POCRT significantly reduces the local relapse and distant metastasis rates, and increases the relapse-free survival rate of the patients with Ⅲa-pN2 NSCLC, however, it fails to raise the overall survival rate. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
